論文

査読有り 国際誌
2021年10月

Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy.

Anticancer research
  • Kazuyuki Hamada
  • Kiyoshi Yoshimura
  • Yuya Hirasawa
  • Masahiro Hosonuma
  • Masakazu Murayama
  • Yoichiro Narikawa
  • Hirotsugu Ariizumi
  • Ryotaro Ohkuma
  • Midori Shida
  • Yutaro Kubota
  • Satoshi Matsukuma
  • Tomoyuki Ishiguro
  • Takehiko Sambe
  • Atsushi Horiike
  • Atsuo Kuramasu
  • Satoshi Wada
  • Junji Tsurutani
  • Eisuke Inoue
  • Naoki Uchida
  • Yuji Kiuchi
  • Shinichi Kobayashi
  • Robert M Hoffman
  • Takuya Tsunoda
  • 全て表示

41
10
開始ページ
4985
終了ページ
4993
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.21873/anticanres.15312

BACKGROUND/AIM: There is an increasing use of immunotherapy for non-small cell lung cancer (NSCLC) patients. The present study analysed the effect of antibiotic use on the outcome of NSCLC patients undergoing treatment with anti-programmed cell death-1 (anti-PD-1) immunotherapy. PATIENTS AND METHODS: This was a retrospective study of 69 NSCLC patients. Eighteen out of 69 patients received antibiotics within 21 days before or within 21 days after start of anti-PD-1 therapy. RESULTS: Patients treated with anti-PD-1 antibodies receiving antibiotics had greatly decreased objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) compared to those who did not use antibiotics. Multivariate analysis showed that antibiotic treatment of patients on anti-PD-1 antibody therapy was an independent negative predictive factor of PFS; however, it was not a significant independent predictive factor of OS. CONCLUSION: Use of antibiotics within 21 days before and after anti-PD-1 treatment initiation in patients with NSCLC strongly reduced OS and PFS, suggesting the two treatments should not be combined.

リンク情報
DOI
https://doi.org/10.21873/anticanres.15312
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34593446
ID情報
  • DOI : 10.21873/anticanres.15312
  • PubMed ID : 34593446

エクスポート
BibTeX RIS